{"log_id": 3970967996087362022, "direction": 0, "words_result_num": 37, "words_result": [{"probability": {"variance": 0.040726, "average": 0.814034, "min": 0.512164}, "location": {"width": 85, "top": 127, "height": 26, "left": 95}, "words": "感神经药"}, {"probability": {"variance": 0.003397, "average": 0.979465, "min": 0.634803}, "location": {"width": 965, "top": 148, "height": 55, "left": 132}, "words": "β受体阻滞剂会掩盖低血糖症状。当接受瑞格列奈治疗的患者使用或停止使用这些药物时,应密切监测患者"}, {"probability": {"variance": 0.039954, "average": 0.899616, "min": 0.499847}, "location": {"width": 106, "top": 222, "height": 27, "left": 94}, "words": "血糖的变化"}, {"probability": {"variance": 3.5e-05, "average": 0.996628, "min": 0.98362}, "location": {"width": 119, "top": 268, "height": 27, "left": 100}, "words": "【药物过量】"}, {"probability": {"variance": 0.006409, "average": 0.970238, "min": 0.553929}, "location": {"width": 936, "top": 292, "height": 51, "left": 160}, "words": "项在2型糖尿病患者中开展的临床试验中,每周增加瑞格列奈的服药量,在超过6周的时间范围内服药"}, {"probability": {"variance": 0.016007, "average": 0.926742, "min": 0.377263}, "location": {"width": 971, "top": 340, "height": 51, "left": 96}, "words": "从4mg增加至20mg。患者每日4次在进餐时服药。除与电糖降低关的可预期的影响外,基本木出现不良事"}, {"probability": {"variance": 0.007227, "average": 0.969333, "min": 0.597122}, "location": {"width": 1000, "top": 388, "height": 52, "left": 94}, "words": "由于该研究中通过增加热量摄取的方法以减少低血糖症状的发生,因此药物相对过量会可能表现为降糖作用的理"}, {"probability": {"variance": 0.025981, "average": 0.924524, "min": 0.372}, "location": {"width": 1001, "top": 434, "height": 50, "left": 96}, "words": "大及出现低血糖症状(头晕、出汗、颤、头等)。口出现这些反应,应采取有效措施纠低血糖(口服懒"}, {"probability": {"variance": 0.008162, "average": 0.946908, "min": 0.634003}, "location": {"width": 820, "top": 483, "height": 51, "left": 97}, "words": "水化合物)更严重的低血糖伴有癫痫、意识丧失和昏逃,这种情况下,应静脉输入葡萄糖"}, {"probability": {"variance": 0.000208, "average": 0.993155, "min": 0.960917}, "location": {"width": 116, "top": 549, "height": 31, "left": 102}, "words": "【药理毒理】"}, {"probability": {"variance": 0.021708, "average": 0.921671, "min": 0.415148}, "location": {"width": 961, "top": 577, "height": 48, "left": 139}, "words": "本品为短效口服降糖药,通过促进胰腺β细胞的胰岛素分泌,降低糖水平。其作用机理是通过与位览"}, {"probability": {"variance": 0.007735, "average": 0.967097, "min": 0.443839}, "location": {"width": 998, "top": 623, "height": 51, "left": 95}, "words": "膜上的特定位点结合,关闭细胞膜上ATP依赖性钾通道,使β细胞去极化,导致其钙通道开放,钙的内流增加"}, {"probability": {"variance": 0.00373, "average": 0.971994, "min": 0.801798}, "location": {"width": 188, "top": 688, "height": 33, "left": 97}, "words": "从而促使胰岛素分泌"}, {"probability": {"variance": 3e-06, "average": 0.99881, "min": 0.994679}, "location": {"width": 135, "top": 737, "height": 27, "left": 103}, "words": "【药代动力学】"}, {"probability": {"variance": 0.015157, "average": 0.925604, "min": 0.520428}, "location": {"width": 963, "top": 766, "height": 49, "left": 138}, "words": "瑞格列奈经胃肠道快速吸收、导致血浆药物浓度迅速升高服药后1小时内浆药物浓度这值然后翻浆"}, {"probability": {"variance": 0.048942, "average": 0.825791, "min": 0.369392}, "location": {"width": 982, "top": 817, "height": 46, "left": 99}, "words": "浓变逃速下,46小时内波清除。血浆衰期约为1小时。瑞格训泰人血浆蛋的结合人于8%端格"}, {"probability": {"variance": 0.045854, "average": 0.839862, "min": 0.373873}, "location": {"width": 993, "top": 862, "height": 49, "left": 103}, "words": "全部被代谢,代谢物木见有任何胎床意义的症糖作用格列杂其代谢广物白胆,很"}, {"probability": {"variance": 0.006893, "average": 0.948878, "min": 0.6495}, "location": {"width": 518, "top": 919, "height": 40, "left": 119}, "words": "小8%)代谢产物口尿排出。粪便中的原形药物少于2%"}, {"probability": {"variance": 0.012356, "average": 0.936778, "min": 0.633116}, "location": {"width": 960, "top": 958, "height": 48, "left": 141}, "words": "据国外文献报道,对肾功能正常(CrCP80 ml/miin)、伴有轻微和中度肾功能损伤(CrCl=40~80 )mlini)和"}, {"probability": {"variance": 0.0079, "average": 0.949962, "min": 0.645423}, "location": {"width": 1002, "top": 1007, "height": 48, "left": 100}, "words": "严重肾功能损伤(CrCl=20-40mL/min)的2型糖尿病患者给予单剂量瑞格列奈后的稳态药动学做了比较肾"}, {"probability": {"variance": 0.02435, "average": 0.929438, "min": 0.358995}, "location": {"width": 999, "top": 1056, "height": 48, "left": 99}, "words": "能正常的患者与伴有轻微和中度肾功能损伤的患者间的AUC和Cm相拟(平均值分别为56.7 ng/il * hr和"}, {"probability": {"variance": 0.003748, "average": 0.95813, "min": 0.830989}, "location": {"width": 195, "top": 1124, "height": 26, "left": 100}, "words": " 57. 2ng/nl*hr: 37. 5ng"}, {"probability": {"variance": 0.008886, "average": 0.955969, "min": 0.46788}, "location": {"width": 768, "top": 1105, "height": 40, "left": 335}, "words": "和37.7ng/mL)。伴有严重肾功能损伤的患者的AUC和Cma均大幅增加(分别为98.0"}, {"probability": {"variance": 0.026469, "average": 0.919914, "min": 0.356854}, "location": {"width": 1000, "top": 1150, "height": 50, "left": 101}, "words": " ny ml *hr利50.7 ng/IL),但是这项研究仅仅表明瑞格列浓度与肌酐清除率(CrC)之间存在微弱的关联、伴"}, {"probability": {"variance": 0.009307, "average": 0.96931, "min": 0.362899}, "location": {"width": 1001, "top": 1199, "height": 46, "left": 102}, "words": "有轻微和中度肾功能损伤的患者无需调整起始剂。然而,伴有严重肾功能损伤的2型糖尿病患者的起始剂量"}, {"probability": {"variance": 4e-06, "average": 0.997801, "min": 0.99578}, "location": {"width": 84, "top": 1266, "height": 24, "left": 100}, "words": "应定为0"}, {"probability": {"variance": 0.004092, "average": 0.969839, "min": 0.710077}, "location": {"width": 864, "top": 1245, "height": 47, "left": 236}, "words": "然后再谨慎地调整剂量。在肌酐清除率低于20mL/min以及需要血液透析的肾衰患者中的研尚"}, {"probability": {"variance": 1.7e-05, "average": 0.997109, "min": 0.989987}, "location": {"width": 84, "top": 1313, "height": 24, "left": 101}, "words": "未开展过"}, {"probability": {"variance": 0.000216, "average": 0.98929, "min": 0.968519}, "location": {"width": 164, "top": 1270, "height": 122, "left": 915}, "words": "限公司"}, {"probability": {"variance": 0.074818, "average": 0.640206, "min": 0.366678}, "location": {"width": 36, "top": 1297, "height": 39, "left": 1059}, "words": "/"}, {"probability": {"variance": 0.009504, "average": 0.955882, "min": 0.626262}, "location": {"width": 942, "top": 1344, "height": 43, "left": 140}, "words": "据国外文献报道,在12名健康受试者和12名按照 Child-Pugh分级和啡因清除率分线的慢性壮病患者"}, {"probability": {"variance": 0.008123, "average": 0.961827, "min": 0.619966}, "location": {"width": 998, "top": 1393, "height": 43, "left": 101}, "words": "展开了一项单剂、标签公开的研究。与健康受试者比,伴有中变至重度肝功能损伤的患者的瑞列余总体"}, {"probability": {"variance": 0.008923, "average": 0.949815, "min": 0.655514}, "location": {"width": 758, "top": 1446, "height": 38, "left": 101}, "words": "药浓度和游离瑞格列奈浓度要高,而且诗续时间史长(健康受试者AUC:9.6mg/ml"}, {"probability": {"variance": 0.034258, "average": 0.852326, "min": 0.393973}, "location": {"width": 178, "top": 1446, "height": 23, "left": 914}, "words": "慢性患AUC:"}, {"probability": {"variance": 0.000445, "average": 0.98414, "min": 0.928985}, "location": {"width": 98, "top": 1510, "height": 22, "left": 100}, "words": "368.9ng/m"}, {"probability": {"variance": 0.006861, "average": 0.95393, "min": 0.544337}, "location": {"width": 847, "top": 1492, "height": 39, "left": 255}, "words": "健康受试者Cmax:46.7ng/mL;慢性肝病患者Cmx:105.4ng/mL)。AUC与咖非因清除率之间"}, {"probability": {"variance": 0.007616, "average": 0.963116, "min": 0.464002}, "location": {"width": 1003, "top": 1538, "height": 42, "left": 101}, "words": "存在统计学上的相关。患者组中没有观察到血糖谱上的差异。在接受普通量的情况卜,肝功能损伤的患者瑞格"}], "language": 3}